Radicle Relief 1: A Study of Health and Wellness Products on Pain and Other Health Outcomes

NCT ID: NCT05589935

Last Updated: 2023-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

457 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-22

Study Completion Date

2023-05-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, blinded, placebo-controlled study assessing the impact of health and wellness products on pain and other health outcomes

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, blinded, placebo-controlled study conducted with up to 300 adult participants per study arm, age 21 and older and residing in the United States.

Eligible participants will (1) endorse a desire for less pain, (2) indicate an interest in taking a health and wellness product to potentially help relieve their pain, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.

Self-reported data are collected electronically from eligible participants over 5 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Nociceptive Pain Neuropathic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be stratified based on gender at birth then randomized to one of the study arms
Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators
The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control 1

Relief Product Form 1 - control

Group Type PLACEBO_COMPARATOR

Relief Study Product Usage

Intervention Type DIETARY_SUPPLEMENT

Participants instructed to use study product daily as directed for a period of 4 weeks

Active Product 1.1

Relief Product Form 1 - active product 1

Group Type EXPERIMENTAL

Relief Study Product Usage

Intervention Type DIETARY_SUPPLEMENT

Participants instructed to use study product daily as directed for a period of 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Relief Study Product Usage

Participants instructed to use study product daily as directed for a period of 4 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities
* Resides in the United States
* Endorses pain as a primary issue (desire for less pain)
* Selects their desire for less pain and/or reduce reliance on medications as a reason for their interest in taking a health and wellness product
* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion Criteria

* Reports being pregnant, trying to become pregnant, or breastfeeding
* Unable to provide a valid physical shipping address
* Reports a diagnosis of liver or kidney disease
* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
* Unable to read and understand English
* Lack of reliable daily access to the internet
* Reports taking anticoagulants, any medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, or MAOIs
* Reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection
Minimum Eligible Age

21 Years

Maximum Eligible Age

105 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Radicle Science

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emily K. Pauli, PharmD

Role: PRINCIPAL_INVESTIGATOR

Radicle Science Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Radicle Science, Inc

Del Mar, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://radiclescience.com

Radicle Science, Inc

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RADX-22D05

Identifier Type: -

Identifier Source: org_study_id